Navigation Links
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Date:9/3/2013

BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS), slightly greater than those who feel the same about Novartis's Gilenya and nearly twice as many as for Genzyme's Aubagio. Conversely, less than one-third of surveyed managed care organization (MCO) pharmacy directors/medical directors (PDs/MDs) identify Gilenya, Aubagio or Tecfidera as breakthrough treatments, perhaps underscoring their decision to most commonly cover all three oral agents on nonpreferred tiers in their largest commercial plans. Notably, approximately one-quarter of surveyed MCO PDs/MDs did not cover Aubagio or Tecfidera at the time the survey was fielded, which is likely due to the recent launches of these agents. 

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician and Payer Forum report entitled The Rapidly Evolving Multiple Sclerosis Treatment Landscape: How Are U.S. Physicians and Payers Responding to the Influx of New Disease-Modifying Therapies?  also finds that two emerging products, Biogen Idec's Plegridy (a pegylated version of Biogen Idec's Avonex) and Teva's Copaxone 40 mg/ml, dosed three-times weekly (a reformulation of Teva's once-daily 20mg/ml Copaxone), will experience usage patterns and market access positioning similar to those of their respective predecessor compounds. This finding suggests that physicians and payers consider the clinical value of these new products to be sufficient to drive use and coverage, but that they lack strong differentiation from their respective
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
5. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
8. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
9. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) ... financial results after the market closes on Tuesday, August ... will be held on Tuesday, August 5, 2014, at ... To participate in the call, please dial 877-303-1298 ... rebroadcast of the teleconference will be available for one ...
(Date:7/22/2014)... July 22, 2014 Legislation backed by ... to Local Pharmacies Act of 2014") championing so-called ... would undermine the availability of lower cost preferred ... billion over the next 10 years, according to ... the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... Pa. , July 22, 2014  Eyeon Therapeutics ... dry eye treatment based on a charged hydrophilic polymer ... The product has been shown to be safe and ... Mitchnick , MD, CEO states, "This first set of ... a long way to moving this technology into the ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... Mass., Dec. 15, 2011  For parents, knowing how to take ... like sweat or drafts affect the accuracy of results can ... Vicks ® Behind ... out of measuring for fever, restoring confidence to parents and ...
... 2011   Enlight Biosciences LLC announced today ... and Novo Nordisk.  As partners in Enlight, AstraZeneca and ... and invest in the development of potentially transformational ... was created by PureTech Ventures in partnership with ...
Cached Medicine Technology:Behind The Ear -- A New Site To Measure for Fever 2Behind The Ear -- A New Site To Measure for Fever 3Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk 2Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk 3
(Date:7/22/2014)... San Antonio, TX (PRWEB) July 22, 2014 ... website. Designed with existing patients and new visitors in mind, ... a clean, modern and visual layout that makes navigation very ... to make the experience of going to the dentist affordable, ... , One helpful new feature is an appointment scheduling ...
(Date:7/22/2014)... Alexandria, Va. (PRWEB) July 22, 2014 ... Sept. 10, at the Ronald Reagan Building and ... “Transitioning Forward: Warriors, Military Families and Civilian Communities,” ... p.m., (registration opens at 7:30 a.m.) and cohosted ... and the National Defense Industrial Association (NDIA). USAA ...
(Date:7/22/2014)... 2014 Aaron Marshall, Corporate Counsel at Northrop ... and Speech Agency for the 2014-2015 fiscal year. He ... appointment, Marshall states, "“Serving on the HASA board has given ... and helps me remember how much others need help." , ... Aaron also has a B.S. in Finance from the University ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... treatments that break up blood clots deep in the veins ... risk. However, one results in a greater risk of bleeding ... of the other treatment, a new study finds. The ... thrombosis (DVT) -- is blood-thinning medications and compression stockings. The ...
(Date:7/22/2014)... 2014) The American Society of Hematology (ASH) ... of California Los Angeles with the 2014 E. ... homeostasis, including the discovery of the iron-regulatory hormone hepcidin ... award, named after the Nobel Prize Laureate and past ... achievements in hematology that have represented a paradigm shift ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... ... Center of Excellence – Their Call Center. , ... (PRWEB) February 2, 2010 -- Sacred Heart Health Systems ... specializing in women,s health, cardiac care, orthopedics, cancer care, and the care of children. ...
... ... to find the balance between investing in the necessary internal resources to implement online ... a dozen online tactics, and identifies where companies are using each tactic in the ... ...
... , EMERYVILLE, Calif. , ... Jamba Juice Company and The California Association for Health, Physical ... today for the "Most People Jumping/Skipping Rope at the Same ... off American Heart Month this morning at 9am , ...
... , WASHINGTON , Feb. 1 ... "Use of Herbal Products and Potential Interactions in Patients with ... of Cardiology, the Council for Responsible Nutrition (CRN), the leading ... statement: , Statement by Douglas MacKay, N.D., vice ...
... , ATLANTA , Feb. 1 Givers ... Renewal Fund at The National Christian Foundation (NCF) at ... to the NCF Haiti Renewal Fund will be matched dollar-for-dollar ... provide long-term support for rebuilding and renewing the country. For ...
... SANTA ANA, Calif. , Feb. 1 Grubb & ... and accepted subscriptions aggregating 2,000,000 shares of its common stock, or ... by the state of Ohio . Ohio residents ... Ellis Healthcare REIT II , Grubb & Ellis Healthcare REIT ...
Cached Medicine News:Health News:Sacred Heart Health Systems Utilizes Call Recording to Enhance Quality Process in Call Center 2Health News:Sacred Heart Health Systems Utilizes Call Recording to Enhance Quality Process in Call Center 3Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Update: Jamba Juice and CAHPERD Break Guinness World Record* for the 'Most People Jumping/Skipping Rope at the Same Time' 2Health News:Update: Jamba Juice and CAHPERD Break Guinness World Record* for the 'Most People Jumping/Skipping Rope at the Same Time' 3Health News:Update: Jamba Juice and CAHPERD Break Guinness World Record* for the 'Most People Jumping/Skipping Rope at the Same Time' 4Health News:Update: Jamba Juice and CAHPERD Break Guinness World Record* for the 'Most People Jumping/Skipping Rope at the Same Time' 5Health News:CRN Questions Accuracy of Herbal Products Article 2Health News:CRN Questions Accuracy of Herbal Products Article 3Health News:CRN Questions Accuracy of Herbal Products Article 4Health News:The National Christian Foundation Offers to Match Gifts to Haiti 2Health News:Grubb & Ellis Healthcare REIT II Meets Ohio's Minimum Offering 2
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
Medicine Products: